(Q35859010)

10 August 2017

1 reference

title

Augmentation therapy for alpha(1)-antitrypsin deficiency (English)

1 reference

10 August 2017

Georges S Juvelekian

1

1 reference

10 August 2017

James K Stoller

series ordinal

2

1 reference

10 August 2017

publication date

1 January 2004

1 reference

10 August 2017

1 reference

10 August 2017

volume

64

1 reference

10 August 2017

issue

16

1 reference

10 August 2017

page(s)

1743-1756

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-200464160-00002

10 August 2017

exact match

0 references

cites work

Alpha-1-antitrypsin augmentation therapy for alpha-1-antitrypsin deficiency

1 reference

12 December 2020

Genetics and respiratory disease. 2. Alpha 1-antitrypsin deficiency, cirrhosis and emphysema

1 reference

12 December 2020

Survival and FEV1 decline in individuals with severe deficiency of alpha1-antitrypsin. The Alpha-1-Antitrypsin Deficiency Registry Study Group

1 reference

12 December 2020

Baseline characteristics of enrollees in the National Heart, Lung and Blood Institute Registry of alpha 1-antitrypsin deficiency. Alpha 1-Antitrypsin Deficiency Registry Study Group

1 reference

12 December 2020

Alpha1-antitrypsin deficiency. 1: epidemiology of alpha1-antitrypsin deficiency

1 reference

12 December 2020

Pharmacokinetic study of alpha1-antitrypsin infusion in alpha1-antitrypsin deficiency

1 reference

12 December 2020

A randomized clinical trial of alpha(1)-antitrypsin augmentation therapy

1 reference

12 December 2020

Use of a highly purified alpha 1-antitrypsin standard to establish ranges for the common normal and deficient alpha 1-antitrypsin phenotypes

1 reference

12 December 2020

The effect of augmentation therapy on bronchial inflammation in alpha1-antitrypsin deficiency

1 reference

12 December 2020

Activation of primary human monocytes by the oxidized form of alpha1-antitrypsin

1 reference

12 December 2020

Alpha-1 antitrypsin deficiency: an under-recognized but important issue for respiratory therapists

1 reference

12 December 2020

Antielastases of the human alveolar structures. Implications for the protease-antiprotease theory of emphysema

1 reference

12 December 2020

Molecular basis of alpha-1-antitrypsin deficiency

1 reference

12 December 2020

Cost-effectiveness of alpha-1 antitrypsin replacement therapy in treatment of congenital chronic obstructive pulmonary disease

1 reference

12 December 2020

Natural History and Life Expectancy in Severe Alpha1-Antitrypsin Deficiency, Pi Z

1 reference

12 December 2020

Biochemical efficacy and safety of a new pooled human plasma alpha(1)-antitrypsin, Respitin.

1 reference

12 December 2020

Alpha-1-antitrypsin and a broad spectrum metalloprotease inhibitor, RS113456, have similar acute anti-inflammatory effects

1 reference

12 December 2020

American Thoracic Society/European Respiratory Society statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency.

1 reference

12 December 2020

Biochemical efficacy and safety of monthly augmentation therapy for alpha 1-antitrypsin deficiency

1 reference

12 December 2020

The role of alpha 1-antitrypsin deficiency in the pathogenesis of immune disorders

1 reference

12 December 2020

Z-type alpha 1-antitrypsin is less competent than M1-type alpha 1-antitrypsin as an inhibitor of neutrophil elastase

1 reference

12 December 2020

Alpha1-antitrypsin deficiency: a position statement of the Canadian Thoracic Society.

1 reference

12 December 2020

Replacement therapy of alpha 1-antitrypsin deficiency. Reversal of protease-antiprotease imbalance within the alveolar structures of PiZ subjects

1 reference

12 December 2020

Alpha 1-antitrypsin-deficient variant Siiyama (Ser53[TCC] to Phe53[TTC]) is prevalent in Japan. Status of alpha 1-antitrypsin deficiency in Japan

1 reference

12 December 2020

Siiyama (serine 53 (TCC) to phenylalanine 53 (TTC)). A new alpha 1-antitrypsin-deficient variant with mutation on a predicted conserved residue of the serpin backbone

1 reference

12 December 2020

Augmentation therapy with alpha1-antitrypsin: patterns of use and adverse events

1 reference

12 December 2020

Short-term supplementation therapy does not affect elastin degradation in severe alpha(1)-antitrypsin deficiency. The American-Italian AATD Study Group

1 reference

12 December 2020

Alpha1-antitrypsin deficiency--a model for conformational diseases

1 reference

12 December 2020

Neutrophil accumulation in the lung in alpha 1-antitrypsin deficiency. Spontaneous release of leukotriene B4 by alveolar macrophages

1 reference

12 December 2020

Cost-effectiveness analysis of augmentation therapy for severe alpha1-antitrypsin deficiency.

1 reference

12 December 2020

Longitudinal follow-up of patients with alpha(1)-protease inhibitor deficiency before and during therapy with IV alpha(1)-protease inhibitor

1 reference

12 December 2020

The pathogenesis of chronic obstructive lung diseases: implications for therapy

1 reference

12 December 2020

Clinical features and natural history of severe alpha 1-antitrypsin deficiency. Roger S. Mitchell Lecture

1 reference

12 December 2020

Should health-care systems pay for replacement therapy in patients with alpha(1)-antitrypsin deficiency? A critical review and cost-effectiveness analysis

1 reference

12 December 2020

Augmentation therapy for severe alpha 1-antitrypsin deficiency: is the jury still out on a trial?

1 reference

12 December 2020

Worldwide racial and ethnic distribution of alpha1-antitrypsin deficiency: summary of an analysis of published genetic epidemiologic surveys

1 reference

12 December 2020

Alpha1-antitrypsin deficiency. 2: genetic aspects of alpha(1)-antitrypsin deficiency: phenotypes and genetic modifiers of emphysema risk

1 reference

12 December 2020

Replacement therapy for alpha 1-antitrypsin deficiency associated with emphysema

1 reference

12 December 2020

Current status of alpha-1-antitrypsin replacement therapy: recommendations for the management of patients with severe hereditary deficiency. Ad Hoc Committee on Alpha-1-Antitrypsin Replacement Therapy of the Standards Committee, Canadian Thoracic So

1 reference

12 December 2020

Does alpha1-antitrypsin augmentation therapy slow the annual decline in FEV1 in patients with severe hereditary alpha1-antitrypsin deficiency? Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL) alpha1-AT study group.

1 reference

12 December 2020

Chronic obstructive pulmonary disease. 1: Susceptibility factors for COPD the genotype-environment interaction

1 reference

12 December 2020

Long-term treatment of alpha1-antitrypsin deficiency-related pulmonary emphysema with human alpha1-antitrypsin. Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL)-alpha1-AT-study group

1 reference

12 December 2020

Molecular basis of the liver and lung disease associated with the alpha 1-antitrypsin deficiency allele Mmalton

1 reference

12 December 2020

Augmentation therapy reduces frequency of lung infections in antitrypsin deficiency: a new hypothesis with supporting data

1 reference

12 December 2020

10.2165/00003495-200464160-00002

Identifiers

DOI

1 reference

Dimensions Publication ID

10 August 2017

1003581106

0 references

1 reference